Upgrade to SI Premium - Free Trial

Jefferies Reiterates Buy Rating on Novavax (NVAX): "capital-light adjuvant platform with improving line-of-sight"

March 12, 2026 2:58 PM
Jefferies analyst Roger Song reiterated a Buy rating and $25.00 price target on Novavax (NASDAQ: NVAX)The analyst commented, "We caught ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments